{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:50:13Z","timestamp":1786989013839,"version":"build-2736575974"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T00:00:00Z","timestamp":1698019200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100022876","name":"Photocure Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100022876","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Open Science"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.euros.2023.10.007","type":"journal-article","created":{"date-parts":[[2023,11,4]],"date-time":"2023-11-04T08:12:21Z","timestamp":1699085541000},"page":"37-46","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Immune Contexture Changes Following Blue Light Cystoscopy with Hexaminolevulinate in Bladder Cancer"],"prefix":"10.1016","volume":"58","author":[{"given":"Sara Kaczor","family":"Elb\u00e6k","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tine Ginnerup","family":"Andreasen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Taber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristine","family":"Young-Halvorsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Neijber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f8rgen Bjerggaard","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Dyrskj\u00f8t","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euros.2023.10.007_b0005","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1308\/003588410X12664192076935","article-title":"Mechanisms of recurrence of Ta\/T1 bladder cancer","volume":"92","author":"Bryan","year":"2010","journal-title":"Ann R Coll Surg Engl"},{"key":"10.1016\/j.euros.2023.10.007_b0010","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European Association of Urology Guidelines on non\u2013muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ)","volume":"81","author":"Babjuk","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2023.10.007_b0015","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.urolonc.2014.04.005","article-title":"Assessment of diagnostic gain with hexaminolevulinate (HAL) in the setting of newly diagnosed non\u2013muscle-invasive bladder cancer with positive results on urine cytology","volume":"32","author":"Neuzillet","year":"2014","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euros.2023.10.007_b0020","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/j.1464-410X.2011.10374.x","article-title":"Treatment changes and long-term recurrence rates after hexaminolevulinate (HAL) fluorescence cystoscopy: does it really make a difference in patients with non-muscle-invasive bladder cancer (NMIBC)?","volume":"109","author":"Geavlete","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.euros.2023.10.007_b0025","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/j.juro.2010.06.148","article-title":"Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer","volume":"184","author":"Stenzl","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.euros.2023.10.007_b0030","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.eururo.2013.07.007","article-title":"Hexyl aminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non\u2013muscle-invasive bladder cancer: a critical review of the current literature","volume":"64","author":"Rink","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2023.10.007_b0035","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.eururo.2013.03.059","article-title":"Photodynamic diagnosis of non\u2013muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data","volume":"64","author":"Burger","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2023.10.007_b0040","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.eururo.2009.11.041","article-title":"Photodynamic diagnosis in non\u2013muscle-invasive bladder cancer: a systematic review and cumulative analysis of prospective studies","volume":"57","author":"Kausch","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2023.10.007_b0045","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.pdpdt.2016.09.009","article-title":"5-Aminolevulinic acid in intraoperative photodynamic therapy of bladder cancer (results of multicenter trial)","volume":"16","author":"Filonenko","year":"2016","journal-title":"Photodiagnosis Photodyn Ther"},{"key":"10.1016\/j.euros.2023.10.007_b0050","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/j.urolonc.2012.02.007","article-title":"Photodynamic therapy of bladder cancer \u2013 a phase I study using hexaminolevulinate (HAL)","volume":"31","author":"Bader","year":"2013","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euros.2023.10.007_b0055","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1021\/jacsau.2c00591","article-title":"Immuno-photodynamic therapy (IPDT): organic photosensitizers and their application in cancer ablation","volume":"3L","author":"Lu","year":"2023","journal-title":"JACS Au"},{"key":"10.1016\/j.euros.2023.10.007_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120763","article-title":"From molecules to nanovectors: current state of the art and applications of photosensitizers in photodynamic therapy","volume":"604","author":"Verger","year":"2021","journal-title":"Int J Pharm"},{"key":"10.1016\/j.euros.2023.10.007_b0065","doi-asserted-by":"crossref","first-page":"e001926","DOI":"10.1136\/jitc-2020-001926","article-title":"Targeting immunogenic cancer cell death by photodynamic therapy: past, present and future","volume":"9","author":"Alzeibak","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.euros.2023.10.007_b0070","doi-asserted-by":"crossref","first-page":"548","DOI":"10.3390\/biomedicines10030548","article-title":"Antitumor effect and induced immune response following exposure of hexaminolevulinate and blue light in combination with checkpoint inhibitor in an orthotopic model of rat bladder cancer","volume":"10","author":"Lamy","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.euros.2023.10.007_b0075","doi-asserted-by":"crossref","first-page":"4858","DOI":"10.1038\/s41467-020-18640-0","article-title":"Molecular correlates of cisplatin-based chemotherapy response in muscle invasive bladder cancer by integrated multi-omics analysis","volume":"11","author":"Taber","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.euros.2023.10.007_b0080","unstructured":"RStudio Team. RStudio: integrated development environment for R. Boston, MA: RStudio PBC; 2022. URL. http:\/\/www.rstudio.com\/."},{"key":"10.1016\/j.euros.2023.10.007_b0085","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.ccell.2018.03.012","article-title":"T cell dysfunction in cancer","volume":"33","author":"Thommen","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.euros.2023.10.007_b0090","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/s41577-019-0257-x","article-title":"B cells, plasma cells and antibody repertoires in the tumour microenvironment","volume":"20","author":"Sharonov","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.euros.2023.10.007_b0095","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.euo.2022.01.008","article-title":"Immune contexture and differentiation features predict outcome in bladder cancer","volume":"5","author":"Taber","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euros.2023.10.007_b0100","unstructured":"Danske Multidisciplin\u00e6re Cancer Grupper. Bl\u00e6recancer. Kliniske retningslinjer. https:\/\/www.dmcg.dk\/Kliniske-retningslinjer\/kliniske-retningslinjer-opdelt-paa-dmcg\/cancer-i-urinvejene\/blaerecancer\/."},{"key":"10.1016\/j.euros.2023.10.007_b0105","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.eururo.2009.09.037","article-title":"Photodynamic diagnosis (5-aminolevulinic acid) of transitional cell carcinoma after bacillus Calmette-Gu\u00e9rin immunotherapy and mitomycin C intravesical therapy","volume":"57","author":"Draga","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2023.10.007_b0110","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s11934-020-0966-5","article-title":"Blue light cystoscopy: indications and outcomes","volume":"21","author":"Pohar","year":"2020","journal-title":"Curr Urol Rep"},{"key":"10.1016\/j.euros.2023.10.007_b0115","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/s41585-019-0184-4","article-title":"Blue light flexible cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on optimal use in the USA \u2013 update 2018","volume":"16","author":"Lotan","year":"2019","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.euros.2023.10.007_b0120","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.euros.2021.06.011","article-title":"Time to turn on the blue lights: a systematic review and meta-analysis of photodynamic diagnosis for bladder cancer","volume":"31","author":"Veeratterapillay","year":"2021","journal-title":"Eur Urol Open Sci"}],"container-title":["European Urology Open Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666168323018098?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666168323018098?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T20:10:47Z","timestamp":1762978247000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666168323018098"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":24,"alternative-id":["S2666168323018098"],"URL":"https:\/\/doi.org\/10.1016\/j.euros.2023.10.007","relation":{},"ISSN":["2666-1683"],"issn-type":[{"value":"2666-1683","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune Contexture Changes Following Blue Light Cystoscopy with Hexaminolevulinate in Bladder Cancer","name":"articletitle","label":"Article Title"},{"value":"European Urology Open Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euros.2023.10.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}